Search Results
Jul 06, 2026, 08:00 ET Matica Bio and VaxDome Partner to Develop Antigen-Agnostic Antiviral-Vaccine Hybrids with Influenza as One of the Disease Models
The project centers on VaxDome's unique approach to broad protection against diverse known / unknown viruses as well as lung cancer by rapid transformation of a selected influenza virus strain into a safe, intranasally delivered, antigen-agnostic antiviral / vaccine hybrid
More news about: Matica Biotechnology, Inc.
Jul 06, 2026, 07:05 ET TransMedics Group Announces Completion of Strategic Investment in PAD Aviation service GmbH
Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the closing of its strategic investment in PAD Aviation, a premier Germany-based private aviation operator.
More news about: TransMedics Group, Inc.
Jul 02, 2026, 10:31 ET Non-Small Cell Lung Cancer Market Poised for Robust Expansion at a 6.6% CAGR Through 2036, Driven by Emerging Targeted and Immunotherapy Innovations | DelveInsight
mutations.What is Non-small Cell Lung Cancer?Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for approximately 85% of all lung cancer cases. It is a heterogeneous group of malignancies that originate from the epithelial cells of the lung and includes several histological
More news about: DelveInsight Business Research, LLP
Jul 02, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Immutep Limited of Class Action Lawsuit and Upcoming Deadlines - IMMP
Monitoring Committee (IDMC) for the TACTI-004 Phase III study evaluating eftilagimod alfa ('efti') in patients in 1st line non-small cell lung cancer has recommended the discontinuation of the trial following a planned interim futility analysis in accordance with the study protocol." According
More news about: Pomerantz LLP
Jul 02, 2026, 06:30 ET Partner Therapeutics Announces Publication of Results From the eNRGy Trial of Zenocutuzumab in Patients with NRG1+ Cholangiocarcinoma in Journal of Clinical Oncology (JCO)
for Grade 4 or life-threatening IRR or hypersensitivity/anaphylaxis reactions.Interstitial Lung Disease/PneumonitisBIZENGRI can cause serious and life-threatening interstitial lung disease (ILD)/pneumonitis.In the eNRGy study, ILD/pneumonitis occurred in 2 (1.1%) patients treated
More news about: Partner Therapeutics, Inc.
Jul 02, 2026, 03:24 ET DJI Agriculture nâng tầm nông nghiệp chính xác với việc ra mắt toàn cầu Agras T55 và hệ thống phun pin kép T100
phun pin kép Agras T100 mang đến tính linh hoạt cao hơn trong nhiều nhiệm vụ nông nghiệp và cải thiện hiệu quả. Với hai pin thông minh, thời gian lơ lửng tăng 50% ở cùng mức tải trọng, trong khi dung tích bình chứa 90 lít bảo đảm thời lượng hoạt động dài hơn - cho phép vận hành liền mạch, không gián đoạn
More news about: DJI
Jul 02, 2026, 00:12 ET Fosun International Garners Five Awards from Corporate Governance Asia
first-line treatment of extensive-stage small cell lung cancer (ES-SCLC), and has been approved for marketing in over 40 countries and regions. HLX43 has shown significant advantages, with a favorable efficacy and safety profile in non-small cell lung cancer (NSCLC), gynecological tumors, esophageal squamous
More news about: Fosun
Jul 01, 2026, 21:00 ET Abbisko Therapeutics and AstraZeneca Enter a Strategic Collaboration to Conduct the Clinical Trial of Lumipodlin (ABSK043), a First-in-Class Oral PD-L1 Inhibitor, in Combination with TAGRISSO® for NSCLC
agreement with AstraZeneca (LSE/STO/NYSE: AZN) to jointly advance the clinical development of a novel IO-TKI combination therapy for non-small cell lung cancer (NSCLC). As a multicenter, open-label Phase I/II clinical study, the combination will evaluate the safety and efficacy of Abbisko's first-in-class
More news about: Abbisko
Jul 01, 2026, 10:00 ET BIOSAPIEN - THE REVOLUTIONARY CANCER PLATFORM DEVELOPER - ANNOUNCES TWO, WORLD-CLASS US MANUFACTURING PARTNERS: ROSWELL PARK AND BA SCIENCES
for MediChip™ in the UAE - concentrating initially on colorectal cancer patients, with scope to subsequently branch out to other cancers (pancreatic, lung), and non-cancer indications.About Roswell ParkFrom the world's first chemotherapy research to the PSA prostate cancer biomarker,
More news about: BioSapien Inc
Jul 01, 2026, 09:00 ET Cumberland Pharmaceuticals Closes Strategic Transaction with Apotex
milestone.Idiopathic Pulmonary Fibrosis:A Phase II study evaluating ifetroban in patients with the most common form of progressive fibrosing interstitial lung disease is actively enrolling at medical centers across the U.S. Favorable interim safety findings have been announced and the next milestone is the
More news about: Cumberland Pharmaceuticals Inc.
Jul 01, 2026, 08:36 ET Cyclone Pods Publishes Raw, Sample-by-Sample Lab Data for Its Nicotine-Free Vapes and Pouches
Disease Control and Prevention as a chemical of concern in samples associated with the 2019 outbreak of e-cigarette, or vaping, product use-associated lung injury (EVALI); diacetyl is a flavoring compound that has been studied for respiratory effects in occupational settings.Cyclone Pods' vapes —
More news about: Cyclone Pods
Jul 01, 2026, 08:17 ET "I Have Decided to Marry Peru": Keiko Fujimori in an Exclusive Interview with Ismael Cala
Family's Final ReconciliationThe emotional climax of the interview centered on Susana Higuchi's final days after being diagnosed with aggressive lung cancer. While she was in intensive care, doctors observed that her body continued resisting in ways they could not medically explain, suggesting that
More news about: Cala Enterprises Corporation
Jul 01, 2026, 08:00 ET Lung Denervation Trial targets Novel COPD Phenotype
company's proprietary dNerva® Lung Denervation System addresses airway hyper-responsiveness, a pathophysiologic underpinning of both COPD and asthma, with a one-time, outpatient procedure designed to improve lung function, exacerbation rates and quality of life.The dNerva® lung denervation system is under
More news about: Nuvaira, Inc.
Jul 01, 2026, 08:00 ET Oncologists Say Cancer Care Starts Too Late - PreOncology™ Launches New Medical Specialty Focused on Finding Cancer Before Stage I
de-identified patient records derived from many of the same large prospective research studies that underpin national cancer screening guidelines. For lung cancer alone, the model incorporates data from more than 611,000 individuals, substantially expanding the evidence base available for individualized
More news about: PreOncology
Jul 01, 2026, 06:04 ET World Bronchiectasis Day: 3 Things to Know About the Irreversible Lung Disease that Impacts 500,000 People in the U.S.
Lung.org/bronchiectasis.About the American Lung AssociationThe American Lung Association is the leading organization working to save lives by improving lung health and preventing lung disease through education, advocacy and research. The work of the American Lung Association is focused on four strategic
More news about: American Lung Association
Jun 30, 2026, 08:00 ET Many Pet Owners May Be Underestimating Heartworm Risk, New Claims Data Shows
mosquito and can affect both dogs and cats. Once infected, worms can live in the heart, lungs, and associated blood vessels, potentially leading to severe lung disease, heart failure, organ damage, and, in some cases, death. Because symptoms may not appear until the disease has progressed, routine testing and
More news about: Embrace Pet Insurance
Jun 29, 2026, 21:04 ET 4DMedical erhält TGA-Zulassung für CT:VQ™ und bringt damit kontrastmittelfreie Ventilations-/Perfusionsbildgebung nach Australien
und präziser erkennen, diagnostizieren und überwachen können.Das wachsende Software-Portfolio von 4DMedical umfasst die FDA-freigegebene XV Lung Ventilation Analysis Software (XV LVAS®), CT LVAS™ sowie die bahnbrechende Lösung CT:VQ™, die durch die Kombination von Ventilations-
More news about: 4DMedical
Jun 29, 2026, 14:22 ET DURING CANCER SURVIVOR MONTH, STATEN ISLAND PATIENT REFLECTS ON WHY PROCURE WAS WORTH THE TRIP
opened in March 2012 as the tri-state region's first proton therapy facility, treating a range of cancers including diseases of the prostate, breast, lung, brain, head and neck, and gastrointestinal system, as well as sarcomas and many pediatric cases. Using the most advanced radiation treatment available,
More news about: ProCure Proton Therapy Center
Jun 29, 2026, 13:57 ET Study Reveals How Leukemia Cells Enter and Damage Lungs
say reducing early breathing crises is crucial to giving AML therapies time to be effective.By examining lung tissue slices from mice, as well as tissue biopsies of patients with AML lung "involvement," the study authors found that AML cancer cells infiltrate the lungs through the thin alveolar wall
More news about: NYU Langone Health System
Jun 29, 2026, 11:49 ET Brayton Purcell LLP Named Finalist for 2026 Trial Lawyer of the Year Award
progressive and fatal lung disease.In recent years, diagnoses have increased, particularly in California, with many individuals affected at relatively young ages. Silicosis results in long-term respiratory impairment, oxygen dependence, and, in severe cases, the need for lung transplantation.Role
More news about: Brayton Purcell LLP
Jun 29, 2026, 09:00 ET TrilliumBiO and The LAM Foundation Partner to Advance LAM Awareness and Education
biomarker discovery and precision diagnostics, today announced a commitment to raising awareness of lymphangioleiomyomatosis (LAM), a rare, progressive lung disease that primarily affects women. As part of this effort, the company is proud to highlight its partnership with The LAM Foundation, the global
More news about: TrilliumBiO
Jun 29, 2026, 08:45 ET Anixa Biosciences Granted First Korean Patent for its Breast Cancer Vaccine, Extending Global Protection Through 2040
breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms
More news about: Anixa Biosciences, Inc.
Jun 29, 2026, 08:00 ET Nuvation Bio Announces Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated in the United Kingdom
for Canada and other regions included in Eisai's licensed territories.Within the U.K., there are around 50,200 new lung cancer cases every year. Around 80 to 85% of all lung cancers are NSCLC, of which approximately 2% of patients harbor the ROS1+ mutation.The application is based on data
More news about: Nuvation Bio Inc.
Jun 29, 2026, 03:10 ET AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata
of tofacitinib (another JAK inhibitor) in RA patients ≥50 years of age with ≥1 additional CV risk factor, a higher rate of malignancies, particularly lung cancer, lymphoma, and non-melanoma skin cancer (NMSC), was observed with tofacitinib compared to tumour necrosis factor (TNF) inhibitors. A higher rate
More news about: AbbVie
Jun 29, 2026, 03:10 ET AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata
of tofacitinib (another JAK inhibitor) in RA patients ≥50 years of age with ≥1 additional CV risk factor, a higher rate of malignancies, particularly lung cancer, lymphoma, and non-melanoma skin cancer (NMSC), was observed with tofacitinib compared to tumour necrosis factor (TNF) inhibitors. A higher rate
More news about: AbbVie